Aligos Therapeutics (ALGS) Operating Income (2019 - 2026)

Aligos Therapeutics has reported Operating Income for 8 years, with the latest figure at -$26.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 39.94% year-over-year to -$26.9 million; the trailing twelve-month figure through Mar 2026 stood at -$12.7 million (up 85.29% YoY), and the FY2025 full-year result was -$5.0 million, up 94.37% from the prior year.
• Operating Income for Q1 2026 stood at -$26.9 million, down from $61.2 million in the prior quarter.
• The five-year high for Operating Income was $61.2 million in Q4 2025, with the low at -$35.6 million in Q1 2022.
• Historically, Operating Income has averaged -$18.0 million across 5 years, with a median of -$20.6 million in 2024.
• The largest YoY upside for Operating Income was 397.41% in 2025 against a maximum downside of 40.88% in 2025.
• Aligos Therapeutics' Operating Income stood at -$22.7 million in 2022, then fell by 14.62% to -$26.0 million in 2023, then increased by 20.9% to -$20.6 million in 2024, then jumped by 397.41% to $61.2 million in 2025, then sank by 144.03% to -$26.9 million in 2026.
• The last three Operating Income figures came in at -$26.9 million (Q1 2026), $61.2 million (Q4 2025), and -$28.4 million (Q3 2025), per Business Quant data.